Recent Quotes (30 days)

You have no recent quotes
chg | %

aTyr Pharma Inc  

(Public, NASDAQ:LIFE)   Watch this stock  
Find more results for LIFE
-0.05 (-0.97%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.05 - 5.45
52 week 2.10 - 6.50
Open 5.15
Vol / Avg. 73,140.00/174,422.00
Mkt cap 151.53M
P/E     -
Div/yield     -
EPS -2.19
Shares 29.71M
Beta     -
Inst. own 76%
Nov 13, 2017
Q3 2017 aTyr Pharma Inc Earnings Release (Estimated) Add to calendar
Sep 26, 2017
aTyr Pharma Inc at Ladenburg Thalmann Healthcare Conference
Sep 6, 2017
aTyr Pharma Inc at Wells Fargo Healthcare Conference
Aug 14, 2017
Q2 2017 aTyr Pharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -76.55% -55.05%
Return on average equity -107.31% -65.06%
Employees 58 -
CDP Score - -


3545 John Hopkins Ct Ste 250
SAN DIEGO, CA 92121-1115
United States - Map
+1-858-7318389 (Phone)
+1-858-7318394 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
John D. Mendlein Ph.D. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
John T. Blake Senior Vice President - Finance
Age: 40
Bio & Compensation  - Reuters
David John King Ph.D. Senior Vice President - Research
Age: 58
Bio & Compensation  - Reuters
Grove Matsuoka Senior Vice President, Product Programs and Planning
Age: 58
Bio & Compensation  - Reuters
Ashraf Amanullah Ph.D. Vice President, Biologics Development and Manufacturing
Age: 49
Bio & Compensation  - Reuters
Sanuj K. Ravindran M.D. Chief Business Officer
Age: 45
Bio & Compensation  - Reuters
Sanjay S. Shukla M.D. Chief Medical Officer
Age: 45
Bio & Compensation  - Reuters
Timothy P. Coughlin CPA Director
Age: 50
Bio & Compensation  - Reuters
Jeffrey S. Hatfield Director
Bio & Compensation  - Reuters